# FDA Approves Generic Drug Application for Cipla Ltd Cipla Ltd received FDA approval for an abbreviated new drug application (ANDA211536) on April 6, 2026, expanding the company's generic portfolio and positioning it to capture market share in a competitive therapeutic segment. The approval strengthens Cipla's presence in the U.S. generics market, supporting revenue growth and reinforcing its status as a key player in affordable pharmaceutical solutions.